New reports examine psychiatric risks of varenicline for smoking cessation.

摘要

But the ISMP has called for a reevalu-ation of the drug's safety in light of the new information and has also urged the FDA to investigate why these reports were not made sooner and whether manufacturers are correctly identifying and submitting serious adverse events within the 15-day time frame."We believe varenicline is unsafe for widespread clinical use and encourage FDA to reassess this drug's safety profile based on this new information and take the necessary steps to mitigate harm," said ISMP earlier this year in its QuarterWatch report on AERS data submitted in the third quarter of 2010.